Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer progressing with riociguat trials

Bayer progressing with riociguat trials

8th October 2008

Bayer has reportedly been progressing with its clinical trials of riociguat in pulmonary hypertension treatment.

So far, the company’s phase II trials yielded positive results and phase III is the next stage, Hays Pharma reported.

Riociguat, a soluble guanylate cyclase stimulator in the vasodilating agent family, was described as “an example of the kind of novel approach to treating cardiovascular disease to which Bayer is committed” by Kemal Malik of the company.

Mr Malik, head of global development and member of the executive committee of Bayer HealthCare, added: “Riociguat has the potential to overcome limitations of current standards of care in pulmonary hypertension.”

Bayer’s anticoagulant drug Xarelto (rivaroxaban) has recently been approved by the European commission.

The once-daily product was designed for the prevention of venous blood clots in the 160,000 adult patients having elective knee or hip replacement surgery in the UK.

Germany-based Bayer AG employs 106,000 people worldwide.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.